Ziopharm Oncology Enrolls First Patient in Phase 1 Trial Evaluating Combination Therapy of Controlled IL-12 and OPDIVO®
Go back to Ziopharm Oncology Enrolls First Patient in Phase 1 Trial Evaluating Combination Therapy of Controlled IL-12 and OPDIVO®| INTREXON CORP (NASDAQ: XON) | Delayed: 4.65 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.65 | 52 Week High | $40.24 | |||
| Open | $1.17 | 52 Week Low | $18.52 | |||
| Day High | $4.65 | P/E | 0.59 | |||
| Day Low | $4.65 | EPS | $7.85 | |||
| Volume | 86,212 | |||||
| ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) | Delayed: 0.87 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.87 | 52 Week High | $13.74 | |||
| Open | $0.87 | 52 Week Low | $4.45 | |||
| Day High | $0.87 | P/E | N/A | |||
| Day Low | $0.87 | EPS | $-0.95 | |||
| Volume | 2,400 | |||||
